attIL12-TIL

attIL12-TIL is an autologous tumor-infiltrating lymphocyte (TIL) cell therapy engineered to express a membrane-anchored, tumor-targeted form of interleukin-12 (IL-12). Developed by the M.D. Anderson Cancer Center, this therapy specifically targets cell-surface vimentin (CSV), a marker frequently expressed on mesenchymal-derived tumor cells and associated with aggressive phenotypes in sarcomas. By anchoring IL-12 to the T cell membrane, the therapy aims to deliver the potent pro-inflammatory effects of the cytokine directly to the tumor microenvironment while minimizing systemic toxicity. This modification is designed to enhance T cell infiltration, overcome the collagen-rich physical barriers of high-grade tumors, and stimulate a robust anti-tumor immune response. It is currently being evaluated in Phase 1 clinical trials for advanced or metastatic soft tissue and bone sarcomas, including liposarcoma.

Other names

T cell membrane-anchored tumor-targeted IL12-modified TIL cell therapyCSV-targeted attIL12-TILT cell membrane-anchored tumor-targeted interleukin-12-modified tumor-infiltrating lymphocyte cell therapy